Cargando…
A Possible Role for HMG-CoA Reductase Inhibitors and Its Association with HMGCR Genetic Variation in Parkinson’s Disease
Parkinson’s disease (PD) is the second most common neurodegenerative disease characterised by both motor- and non-motor symptoms, including cognitive impairment. The aetiopathogenesis of PD, as well as its protective and susceptibility factors, are still elusive. Neuroprotective effects of 3-hydroxy...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8620375/ https://www.ncbi.nlm.nih.gov/pubmed/34830081 http://dx.doi.org/10.3390/ijms222212198 |
_version_ | 1784605205331968000 |
---|---|
author | Pierzchlińska, Anna Droździk, Marek Białecka, Monika |
author_facet | Pierzchlińska, Anna Droździk, Marek Białecka, Monika |
author_sort | Pierzchlińska, Anna |
collection | PubMed |
description | Parkinson’s disease (PD) is the second most common neurodegenerative disease characterised by both motor- and non-motor symptoms, including cognitive impairment. The aetiopathogenesis of PD, as well as its protective and susceptibility factors, are still elusive. Neuroprotective effects of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors—statins—via both cholesterol-dependent and independent mechanisms have been shown in animal and cell culture models. However, the available data provide conflicting results on the role of statin treatment in PD patients. Moreover, cholesterol is a vital component for brain functions and may be considered as protective against PD. We present possible statin effects on PD under the hypothesis that they may depend on the HMG-CoA reductase gene (HMGCR) variability, such as haplotype 7, which was shown to affect cholesterol synthesis and statin treatment outcome, diminishing possible neuroprotection associated with HMG-CoA reductase inhibitors administration. Statins are among the most prescribed groups of drugs. Thus, it seems important to review the available data in the context of their possible neuroprotective effects in PD, and the HMG-CoA reductase gene’s genetic variability. |
format | Online Article Text |
id | pubmed-8620375 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-86203752021-11-27 A Possible Role for HMG-CoA Reductase Inhibitors and Its Association with HMGCR Genetic Variation in Parkinson’s Disease Pierzchlińska, Anna Droździk, Marek Białecka, Monika Int J Mol Sci Review Parkinson’s disease (PD) is the second most common neurodegenerative disease characterised by both motor- and non-motor symptoms, including cognitive impairment. The aetiopathogenesis of PD, as well as its protective and susceptibility factors, are still elusive. Neuroprotective effects of 3-hydroxy-3-methyl-glutaryl-coenzyme A (HMG-CoA) reductase inhibitors—statins—via both cholesterol-dependent and independent mechanisms have been shown in animal and cell culture models. However, the available data provide conflicting results on the role of statin treatment in PD patients. Moreover, cholesterol is a vital component for brain functions and may be considered as protective against PD. We present possible statin effects on PD under the hypothesis that they may depend on the HMG-CoA reductase gene (HMGCR) variability, such as haplotype 7, which was shown to affect cholesterol synthesis and statin treatment outcome, diminishing possible neuroprotection associated with HMG-CoA reductase inhibitors administration. Statins are among the most prescribed groups of drugs. Thus, it seems important to review the available data in the context of their possible neuroprotective effects in PD, and the HMG-CoA reductase gene’s genetic variability. MDPI 2021-11-11 /pmc/articles/PMC8620375/ /pubmed/34830081 http://dx.doi.org/10.3390/ijms222212198 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Pierzchlińska, Anna Droździk, Marek Białecka, Monika A Possible Role for HMG-CoA Reductase Inhibitors and Its Association with HMGCR Genetic Variation in Parkinson’s Disease |
title | A Possible Role for HMG-CoA Reductase Inhibitors and Its Association with HMGCR Genetic Variation in Parkinson’s Disease |
title_full | A Possible Role for HMG-CoA Reductase Inhibitors and Its Association with HMGCR Genetic Variation in Parkinson’s Disease |
title_fullStr | A Possible Role for HMG-CoA Reductase Inhibitors and Its Association with HMGCR Genetic Variation in Parkinson’s Disease |
title_full_unstemmed | A Possible Role for HMG-CoA Reductase Inhibitors and Its Association with HMGCR Genetic Variation in Parkinson’s Disease |
title_short | A Possible Role for HMG-CoA Reductase Inhibitors and Its Association with HMGCR Genetic Variation in Parkinson’s Disease |
title_sort | possible role for hmg-coa reductase inhibitors and its association with hmgcr genetic variation in parkinson’s disease |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8620375/ https://www.ncbi.nlm.nih.gov/pubmed/34830081 http://dx.doi.org/10.3390/ijms222212198 |
work_keys_str_mv | AT pierzchlinskaanna apossibleroleforhmgcoareductaseinhibitorsanditsassociationwithhmgcrgeneticvariationinparkinsonsdisease AT drozdzikmarek apossibleroleforhmgcoareductaseinhibitorsanditsassociationwithhmgcrgeneticvariationinparkinsonsdisease AT białeckamonika apossibleroleforhmgcoareductaseinhibitorsanditsassociationwithhmgcrgeneticvariationinparkinsonsdisease AT pierzchlinskaanna possibleroleforhmgcoareductaseinhibitorsanditsassociationwithhmgcrgeneticvariationinparkinsonsdisease AT drozdzikmarek possibleroleforhmgcoareductaseinhibitorsanditsassociationwithhmgcrgeneticvariationinparkinsonsdisease AT białeckamonika possibleroleforhmgcoareductaseinhibitorsanditsassociationwithhmgcrgeneticvariationinparkinsonsdisease |